Trial Design and Oversight
The ACTIV-4a trial, supported by the National Institutes of Health, was designed to evaluate the effects of antithrombotic therapies in patients hospitalized with COVID-19. The trial, coordinated at NYU Grossman School of Medicine and the University of Pittsburgh, enrolls participants across a collaborative consortium of clinical trial networks. The trial is an adaptive platform trial that uses a master protocol to longitudinally study multiple investigational treatments.ACTIV-4a Investigators and collaborators are listed in eAppendix 1 in 